News & Updates

Bedtime dosing of antihypertensive medication is neither better nor worse than morning dosing when it comes to the subsequent risk of all-cause or cardiovascular mortality, according to a study.

Capivasertib, when added to fulvestrant, prolonged progression-free survival (PFS) by 4.1 months in an analysis of Chinese patients with hormone receptor–positive (HR+), HER2-negative (HER2– ABC) advanced breast cancer (ABC) whose disease had progressed on aromatase inhibitor, with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in the phase III CAPItello-291 trial.

Patients with liver disease develop antibodies and T-cell responses following three shots of COVID-19 vaccines, while those who have been infected with SARS-CoV-2 develop mild symptoms only, reports a recent study.